Genflow Biosciences is developing treatments that reduce or delay age-related diseases. The company is London-based, but the research and development is undertaken in Belgium. There is already a compound in pre-clinical trials.
Chief executive Dr Eric Leire is the founder of the business and still owns more than two-fifths of the company. He has two decades of experience in cell and gene therapies.
The share price opened at 9.25p and ended the day at 11.5p. There were 2.16 million shares traded.
This is an early-stage company, and it will be back for more cash in the future. The shar...